News & Media

Read about our latest news and initiatives, and find more information about Acadia. 

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.

Assets & Materials

Contacts

Media

Acadia Contact

Deb Kazenelson

Phone

(818) 395-3043

Investors

Acadia Contact

Al Kildani

Phone

(858) 261-2872